A Contemporary Role of Beta Blockers in Myocardial Infarction

Myocardial infarction (MI) is characterized by plaque formation in the inner layer of arteries which occurs due to insufficient or complete cessation of oxygen supply in the myocardium. The common symptoms of MI are crushing or squeezing chest pain which radiates to the arms, shoulders, neck, or jaw, nausea, anxiety, restlessness, fear, heartburn, shortness of breath, cold sweat, fatigue, and dizziness. The treatment of this medical condition includes antiplatelet and thrombolytic therapy, painkillers (morphine or meperidine), diuretics and digitalis glycosides drugs. Moreover, nitroglycerin and antihypertensive drugs such as Beta-blockers, ACE inhibitors, or Calcium channel blockers may also be administered to reduce the blood pressure and improve the oxygen supply in the heart. Among them, beta blocker therapy has several beneficial properties such as it reduces myocardial oxygen demand, preventing arrhythmias, and improves ventricular remodeling, etc. However, there is no study on the role of only beta blocker therapy in the survival of MI patent is found to date. Thus, the present study focused on the evidence-based validation of Beta blocker therapy in the treatment and survival of MI patients. The retrospective study was conducted on 51 MI patients under the observation of medical practitioners. 100% of patients with MI showed a good recovery as well as survival percentage with Beta blocker therapy. This study finally concluded that beta blocker therapy is a safe and effective treatment for MI patients with negligible life-threatening medical conditions. Furthermore, a large group study is suggested with a number of health-related parameters for a better understanding of beta blocker as a first line of treatment for MI patients.